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Abstract
Background: Men with prostate cancer are often castrated with long-acting injectable drugs termed androgen
deprivation therapy (ADT). Although many benefit, ADT is also used in patients with little or nothing to gain. The
best ways to stop this practice are unknown, and range from blunt pharmacy restrictions to informed decision-
making. This study will refine and pilot two different de-implementation strategies for reducing ADT use among
those unlikely to benefit in preparation for a comparative effectiveness trial.
Methods/design: This innovative mixed methods research program has three aims. Aim 1: To assess preferences
and barriers for de-implementation of chemical castration in prostate cancer. Guided by the theoretical domains
framework (TDF), urologists and patients from facilities with the highest and lowest castration rates across the VA
will be interviewed to identify key preferences and de-implementation barriers for reducing castration as prostate
cancer treatment. This qualitative work will inform Aim 2 while gathering rich information for two proposed pilot
intervention strategies. Aim 2: To use a discrete choice experiment (DCE), a novel barrier prioritization approach, for
de-implementation strategy tailoring. The investigators will conduct national surveys of urologists to prioritize key
barriers identified in Aim 1 for stopping incident castration as localized prostate cancer treatment using a DCE
experiment design. These quantitative results will identify the most important barriers to be addressed through
tailoring of two pilot de-implementation strategies in preparation for Aim 3 piloting. Aim 3: To pilot two tailored
de-implementation strategies to reduce castration as localized prostate cancer treatment. Building on findings from
Aims 1 and 2, two de-implementation strategies will be piloted. One strategy will focus on formulary restriction at
the organizational level and the other on physician/patient informed decision-making at different facilities.
Outcomes will include acceptability, feasibility, and scalability in preparation for an effectiveness trial comparing
these two widely varying de-implementation strategies.
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Discussion: Our innovative approach to de-implementation strategy development is directly aligned with state-of-
the-art complex implementation intervention development and implementation science. This work will broadly
advance de-implementation science for low value cancer care, and foster participation in our de-implementation
evaluation trial by addressing barriers, facilitators, and concerns through pilot tailoring.
Trial registration: ClinicalTrials.gov Identifier: NCT03579680, First Posted July 6, 2018.
Keywords: Castration, De-implementation, Choosing wisely, Low value care, Implementation science, Intervention,
Formulary restriction, Decision-making, Behavior change, Discrete choice, Stakeholder, Androgen deprivation
therapy (ADT),
Background
Prostate cancer is the most common male cancer in the
USA [1]. One in three men with prostate cancer is
chemically castrated at some point with long-acting in-
jectable drugs (i.e., androgen deprivation therapy or
ADT) [2]. This impacts the well-being of thousands of
men annually. Although some patients with prostate
cancer benefit from ADT in terms of survival and symp-
tom improvement, chemical castration is also commonly
performed when there is no high level evidence for use
and little to no health benefits to patients raising ques-
tions of low value care. A growing awareness of iatro-
genic harms (e.g., heart attack, osteoporosis, diabetes,
loss of sexual function) [3], coupled with a lack of evi-
dence supporting chemical castration in many cases [1,
4–6], creates patient safety concerns. Despite this, chem-
ical castration with ADT in low value cases persists as in
the case of localized prostate cancer treatment [7].
Because prostate cancer cells are dependent on andro-
gens, e.g., testosterone, androgen deprivation with cas-
tration can improve clinical outcomes, for some patients
[8]. The highest levels of evidence for chemical castra-
tion with ADT injections to treat prostate cancer occur
in two scenarios: (1) high risk localized disease in com-
bination with radiation therapy, and (2) metastatic can-
cer with spread to bones or other organs causing
symptoms such as pain [8–11]. However, a significant
amount of castration among patients receiving
fee-for-service or integrated health system care occurs
outside those instances where high levels of benefit exist
[1, 4–7]. Neither long-term studies nor current guide-
lines support castration as primary treatment for local-
ized prostate cancer [11]. For example, using castration
for the primary treatment of localized prostate cancer
does not improve prostate cancer-specific survival and
can be harmful [12], yet remains common in the US
Veterans Health Administration [13], a large publicly
funded integrated health system, as well as among pa-
tients in the US Medicare system [14]. Many times, this
castration, which is potentially reversible, is continued
indefinitely without clear indication. Even in cases of
metastatic prostate cancer without symptoms, an Ameri-
can Society of Clinical Oncology Panel could not recom-
mend initiating treatment with ADT before symptoms
of disease progression (e.g., bone pain) occur due to the
lack of evidence of an overall survival advantage for early
treatment [15].
There are several possible reasons why low value ADT
in the treatment of localized prostate cancer persists.
First, ADT decreases the serum PSA level, a biomarker
of prostate cancer activity, providing false reassurance of
a “remission.” This is potentially harmful in a couple of
ways. Depriving prostate cancer cells of testosterone too
early in the disease process may foster castration resist-
ance, limiting ADT’s effectiveness when it may actually
be needed later (e.g., metastatic setting) [16, 17], and
PSA is a poor surrogate marker for survival in localized
disease so a lowered PSA in this setting creates false op-
timism [18]. Second, surgical specialists are prescribing a
drug with potentially devastating metabolic and cardio-
vascular effects creating a disconnect between treating
PSA levels among men with localized disease and the
consequences. Primary care providers are often left to
deal with this combination of treating PSA levels with-
out good evidence, and the significant negative health
consequences for the patient [19–22].
Ineffective and harmful practices such as chemical cas-
tration of patients with prostate cancer outside of the
evidence base are ripe for de-implementation.
De-implementation, or stopping low value practices, has
the potential to improve patient outcomes and decrease
healthcare costs [23–26]. For example, stopping chem-
ical castration for localized prostate cancer treatment
could prevent harm, and limit spending without affect-
ing survival. However, provider and patient preferences
regarding de-implementation are not well understood,
and possible de-implementation interventions range
from blunt policies to more informed decision-making,
potentially with decision support tools to facilitate
unlearning [23, 27–29]. Blunt policy interventions such
as formulary restriction of ADT (e.g., pre-authorization,
order templates) might seem warranted given patient
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safety concerns, yet could result in significant provider
resistance, work-arounds, and even a chilling effect on
evidence-supported use of ADT if introduced poorly
[30–43]. More nuanced, patient-centered interventions
such as informed decision-making (e.g., decision aid,
values elicitation) likely involve extra clinical time [44–
46]. Both intervention strategies need tailoring for ac-
ceptability and feasibility in clinical practice, including
piloting prior to trialing [47]. The messaging and oper-
ation of strategies to stop low value cancer care hinges
on stakeholder input. As many medical practices lack
evidence and cause harm, robust behavioral
theory-based methods for incorporating provider prefer-
ences into de-implementation strategy development will
advance both implementation research and practice.
While lowering PSA might make sense on the surface,
understanding beliefs and preferences for using ADT is
a critical step in stopping its low value use. In many re-
spects, this is an ideal model for understanding
de-implementation of low value cancer care.
Our preliminary data indicate thousands of men are at
risk of ongoing low value castration, especially those with
localized disease. Indeed, this calls for effective
de-implementation strategies grounded in an understand-
ing of context, provider and patient preferences, and
evidence-based behavior change techniques to overcome
the wide variation in practice patterns we have observed
[48–57]. A significant scientific and clinical knowledge gap
remains in prioritizing which barriers to stopping castration
in low value settings need to be targeted for effective
de-implementation. While a major focus in this study per-
tains to identifying, prioritizing, and overcoming barriers,
the facilitators for stopping ADT which may be transferable
across settings also need to be considered [58]. Using a
discrete choice experiment (DCE) will allow prioritization
of both positive (facilitators, preferences) and negative fac-
tors (barriers) to guide theory-based de-implementation
strategies as a promising stakeholder-based approach ap-
plicable to other low value cancer care [59–63].
Methods/design
For these reasons, we will examine urologist and patient
perspectives on chemical castration with ADT in low
value conditions, i.e., as localized prostate cancer treat-
ment. Using a theory-based, exploratory-sequential
mixed methods approach to tailor different
de-implementation strategies, we will pilot interventions
to prepare for a pragmatic, randomized comparative ef-
fectiveness trial of two different approaches that vary
widely in delivery, impact, and expected results for redu-
cing low value ADT use. We have three specific aims:
Aim 1: To assess preferences and barriers for de-
implementation of chemical castration in prostate
cancer. Guided by the theoretical domains framework
(TDF) [49, 64, 65], we will interview urologists and pa-
tients from facilities with the highest, and a few of the
lowest, castration rates across an integrated delivery sys-
tem to identify key preferences and de-implementation
barriers, as well as facilitators, for reducing castration as
prostate cancer treatment. This qualitative work will in-
form Aim 2 and gather rich information for our pro-
posed pilot intervention strategies.
Aim 2: To use a discrete choice experiment, a novel
barrier prioritization approach, for de-implementation
strategy tailoring. We will conduct a national survey of
urologists to prioritize the key barriers identified in Aim
1 for not recommending castration as localized prostate
cancer treatment using a DCE. These quantitative results
will identify the most important barriers to be addressed
through tailoring of our two pilot de-implementation
strategies in preparation for Aim 3 piloting.
Aim 3: To pilot two tailored de-implementation strat-
egies to reduce castration as localized prostate cancer
treatment. Building on findings from Aims 1 and 2, we
will refine two pilot de-implementation strategies. One
strategy will focus on formulary restriction at the
organizational level, and the other on decision-making
at the physician/patient level. Outcomes will include
acceptability, feasibility, and scalability [66] in prepar-
ation for an effectiveness trial comparing these two
widely varying de-implementation strategies across the
integrated delivery system.
Conceptual framework
It is useful to consider a conceptual model for
theory-based qualitative barrier assessment (Aim 1),
quantitative prioritization (Aim 2), and piloting of
de-implementation strategies tailored to provider behav-
ior change techniques (Aim 3). As illustrated in Fig. 1,
we highlight several TDF domains and constructs in our
conceptual model that may contribute to organizational,
provider, and patient behavior in the setting of ADT for
localized prostate cancer. In addition, our qualitative ap-
proach allows for flexibility as we conceptualize the
main issues when it comes to chemical castration. Last,
the quantitative discrete choice methods (Aim 2) create
significant opportunities to examine interactions among
domains and constructs allowing us to select, tailor, and
pilot the most informed organizational and individual
level de-implementation interventions during Aim 3.
Setting
This study is being conducted across several sites in the
Veterans Health Administration with the majority of
study activities at two sites: the VA Health Services Re-
search & Development Center for Clinical Management
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Research at the VA Ann Arbor Healthcare System and the
Rogel Cancer Center at the University of Michigan.
Study population and eligibility criteria
We will identify potential study participants using
methods successfully used in prior studies of VA pro-
viders and prostate cancer survivors [67, 68]. Specifically
for the Aim 1 semi-structured provider interviews, we
will purposefully sample 10–12 urologists from our inte-
grated delivery system facilities with the highest use of
castration as primary treatment to achieve thematic sat-
uration. Likewise, we will also sample 2–4 urologists
from facilities with the lowest use of castration. Any ur-
ologist who has experience caring for prostate cancer
patients on ADT and expresses interest in prostate can-
cer care will be eligible to participate in semi-structured
interviews. We will consider interviewing non-physician
providers (e.g., nurse practitioners) if they prescribe a
significant amount of ADT. To better understand pa-
tient perspectives on not initiating or stopping castration
with ADT, we also plan to conduct a limited number of
patient interviews (~ 6) from high outlier sites.
For the Aim 2 DCE, we will distribute invitations to the
national VA Urology listserv which includes approximately
250 VA urologists. We anticipate this survey will be avail-
able over the intranet, as an online survey, as well as
available in paper and pen form if preferred. We will use a
modified Dillman technique to enhance response rates
similar to prior successful survey research [69]. Our en-
gagement with the national VA Urology listserv and the
American Urological Association Annual Meeting, along-
side operational support from the VA Urology Surgery Ad-
visory Board, should ensure that at least the minimum
number of providers needed participate. If needed, we can
pursue other organizations (e.g., American Urological Asso-
ciation, Society of Urologic Oncology) given our prominent
urologic oncology team.
For Aim 3, we will conduct pilot testing at two sites
during years 3 and 4 of this proposal. This will take
place at the VA Ann Arbor Healthcare System and Uni-
versity of Michigan’s Rogel Cancer Center Urologic On-
cology clinics. The number of patients initiating primary
ADT at each site should be adequate for piloting based
on preliminary data. However, the primary purpose of
the pilots is to assess for issues described in more detail
below [70], not effectiveness, so the number of patients
on ADT is not critical to success for pilot outcomes.
Potential human subjects risks and protections against
them
This proposal received Institutional Review Board ap-
proval from the VA Ann Arbor Healthcare System and
Fig. 1 Conceptual model for de-implementation of low value prostate cancer care
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the University of Michigan. Aim 1 initially involves ana-
lyses of retrospective administrative data to identify facil-
ities, their characteristics, and ADT utilization rates.
Study data will come from the VA Corporate Data
Warehouse and its Oncology database. This is a cen-
trally maintained national electronic data repository con-
sisting of cancer registry, laboratory, pharmacy,
utilization, and administrative data for all patients re-
ceiving care in the delivery system. Reported data will be
aggregated to the facility level which will not permit
identification of individual patients or providers. Next,
we will conduct semi-structured interviews with pro-
viders and a limited number of patients from facilities
with the highest ADT treatment rates for localized pros-
tate cancer. We will audiotape and analyze this data in
Aim 1. The risks of the proposed semi-structured inter-
views are limited, but do include psychological stress re-
lated to discussions of appropriateness of prostate
cancer treatment with ADT and possible tensions given
the low levels of evidence supporting ADT use in local-
ized disease. Another risk is the potential breach of con-
fidentiality of this interview data. Precautions will be
taken to protect against any such breach, making the
risk low, following standard operating procedures at our
Center. Potential human subjects’ risks for the national
survey in Aim 2 are low including an email and minimal
disruption to provider work flow. With the exception of
some demographic information (e.g., age in 5-year incre-
ments), the participant information and responses will
be kept anonymous. Aim 3 risks for pilot site providers
include disruption of clinical workflow and a low likeli-
hood of psychological distress. These risks will be site-
and intervention-dependent with a research assistant
on-site to assist with recruitment, acceptability of the
intervention, feasibility in clinical practice, and data col-
lection and outcome assessment issues. The right of sub-
jects to discontinue their involvement in the research at
any time will also be fully disclosed during the informed
consent process.
Participant recruitment and consent
For the qualitative portions of Aim 1, in person and tele-
phone interviews will be piloted with providers at the
VA Ann Arbor Healthcare System followed by 12–16
urologists from several other VA Medical Centers as de-
scribed. Medical Center Directors and Chief Urologists
will be contacted via email and brief telephone calls ini-
tially and will also be provided information on the na-
ture and purpose of the study, as well as the types of
questions their providers will be asked. With approval,
urologists who express an interest in participation will
be consented by a trained research assistant, who will
provide them with information on the nature and pur-
pose of the study, as well as the types of questions that
they will be asked (focused on ADT treatment for pros-
tate cancer). Written or recorded phone consent will be
obtained. Those who are eligible will then be called at a
later date for a formal interview lasting approximately
45 min. Interviews will be conducted by the study team
and will be audiotaped. We will use similar recruitment
methods for our limited number of patient interviews.
For the survey portion of Aim 2, providers will be
identified through a national urologist email listserv and
contacted/recruited via email to participate in a DCE
survey. An informed consent form will be included,
highlighting the nature and purpose of the proposed re-
search as well as sample questions. Participants will be
asked to electronically sign the consent form, and will be
clearly offered the option of not participating.
Urologists at the pilot sites in Aim 3 will be given an
overview of the site-specific intervention, highlighting
the nature and purpose of the proposed research, as well
as what they should expect to encounter during routine
clinical care should they agree to proceed with the study.
Pilot site urologists will be asked to sign the consent
form by the site research assistant, if they agree to par-
ticipate, and will be clearly offered the option of not
participating.
Aim 1 methods
The goal of Aim 1 is to clarify barriers and facilitators to
stopping castration with ADT as primary prostate cancer
treatment using an individual behavior change frame-
work, the theoretical domains framework (TDF) [71].
This approach will identify key barriers to
de-implementation of low value ADT-based castration.
We will conduct semi-structured interviews with urolo-
gists to clarify preferences for (i.e., facilitators) and bar-
riers to stopping ADT use. This will prepare us for
development of a theory-based DCE among a national
sample of urologists in Aim 2 to quantify the relative
importance of barriers, and to direct intervention strat-
egy tailoring to increase acceptability and effectiveness.
Embedding use of the TDF within a DCE is particularly
innovative.
Semi-structured provider and patient interviews
In order to maximize the likelihood that data collected
from participants will address our study aims, we will
pilot interviews with consultants and providers on our
study team. Using the TDF to understand provider and
patient ADT behavior will help (1) map our findings to
key TDF behavioral constructs; (2) select appropriate
evidence-based behavior change techniques (BCTs) [72,
73]; (3) understand barriers, facilitators, and stated pref-
erences for our de-implementation interventions; and
(4) advance implementation science. We will explore
provider and patient (1) understanding of ADT as
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primary prostate cancer treatment, (2) harms of castra-
tion, (3) behavioral determinants and barriers to deliver-
ing (receiving for patients) ADT as primary prostate
cancer treatment for localized prostate cancer, and (4)
intention to treat localized prostate cancer with ADT.
Interviews will be audiotaped and transcribed verbatim
for content. We will use a preliminary coding scheme
based on the TDF and prior work [52, 74], consisting of
a three step process including (1) coding affirmative and
negative utterances regarding ADT use as localized
treatment into TDF domains, (2) collecting responses
across respondents into themes (e.g., “ADT prevents
cancer spread” into a “ADT is beneficial” theme, “urolo-
gists should be able to treat patients as they wish” into a
“Physician autonomy” theme), and (3) tallying the total
number of mentions per theme, as well as conflicting be-
liefs within a theme (e.g., ADT is good vs. ADT is bad),
according to the TDF domains, with particular emphasis
on those included in our conceptual model. The princi-
pal investigator and research assistant will both inde-
pendently review and code at least two transcripts and
meet regularly to compare coding results until reaching
agreement on code definitions and establish the reliabil-
ity of the coding process (> 80% simple agreement). Dur-
ing this process, the research team will also meet to
categorize the codes into TDF domains, identify emer-
ging themes, and document ongoing data interpretation
in memos. The research assistant will code the
remaining transcripts. Once data are coded, we will use
QSR NVivo™ software to organize the data. The research
team will meet regularly to discuss code summaries and
memos, developing findings with a focus on informing
the Aim 2 discrete choice tool [75]. At the end of this
aim, we will have identified the highest frequency
themes and themes with conflicting provider and patient
beliefs across TDF domains for de-implementing ADT.
Aim 2 methods
The goal of Aim 2 is to then prioritize barriers and facil-
itators to de-implementation of chemical castration with
ADT discovered in Aim 1. The highest priority barriers
will need to be addressed during strategy development
and tailoring for our pilot interventions in Aim 3 to sup-
port acceptability and feasibility in practice. We will ac-
complish this using a DCE. This stated preference
method drives marketing strategy development based on
stakeholder preferences for a given practice and is a
promising applied approach for health care optimization
[59–62, 76, 77]. Real-world DCE examples include pri-
oritizing provider preferences related to hospital consult-
ant work and electronic medical record use [78, 79].
In our DCE, the barriers and themes with the highest
frequency and most conflicting beliefs across respon-
dents identified in Aim 1 will be refined and presented
as the “attributes” and associated levels will be devel-
oped. In short, we will use data obtained from Aim 1 to
develop TDF-based choice sets for inclusion in a na-
tional urologist DCE. Once we have the most important,
not just most common or conflicting, themes and bar-
riers based on a national urologist DCE, we can select
the most effective evidence-based behavior change tech-
niques to direct de-implementation tailoring efforts in
Aim 3.
In a DCE, stakeholders, in this case urologists pre-
scribing ADT, choose between hypothetical alternatives
described by themes and barrier characteristics identified
from Aim 1 (i.e., attributes and levels). The five or six
highest frequency and most conflicting themes based on
Aim 1 findings will be varied across hypothetical exam-
ples. Through systematically varying a set of levels in a
series of choice sets where providers are asked which
option they most prefer, we gather critical data on cas-
tration preferences and tailoring for our pilot interven-
tions. This results in a preference structure where
certain attributes (barriers) are most important across
the respondent sample. The data obtained on the levels
of attributes shows which direction the attribute is most
favored. In an example of whether high or low physician
autonomy or level of evidence is driving ADT treatment
decisions, for each choice set given, we will ask respon-
dents to choose the situation that they would most pre-
fer when prescribing ADT for their prostate cancer
patients (choice A, choice B, or neither). We may ask
participants: “Please select the situation that you most
prefer when prescribing ADT as primary treatment.”
Candidate themes, attributes, and levels include, for ex-
ample, the ability to make the final recommendation
(levels: yes, no), and the amount of clinical time required
(levels: 15 min, 30 min). We will use an opt-out option
to ensure realistic scenarios. Data from this DCE survey
will identify leading themes and attributes (barriers).
Designing and fielding the national urologist DCE
We will decide on the number of attributes based on
Aim 1 findings, likely 4–6 per scenario as suggested by
the literature [63]. The DCE will measure TDF-based
themes across 10–20 choice sets, pared down using a
fractional factorial approach, to a reasonable number of
hypothetical scenarios per respondent to minimize re-
spondent burden. We will use software to construct the
choice sets to identify the least number of choice sets
completed by the least number of respondents to detect
significant differences among covariates in our model.
We will draft a DCE survey tool for refinement and
pre-testing on our study team and a sample of urolo-
gists. We will modify it accordingly based on pre-testing.
We will then distribute invitations to participate to the
national VA Urology listserv which includes
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approximately 250 VA urologists. As described above,
we may include other organizations if our response rate
is lower than expected.
DCE statistical analysis Discrete choice experiments
are based on random utility theory which assumes that
participants will select responses with the most personal
utility [78]. Because respondents respond to a variety of
choice sets, we will be able to estimate the relative prior-
ity of our barrier attributes and their levels. We will
model urologists’ stated preferences providing quantita-
tive information about the relative value, or utility, pro-
viders place on barrier attributes such as physician
autonomy or clinical time, for example, using the equa-
tions below. If 50% of the 250 urologists respond: 125
surveys with ~ 5 scenarios − 625 scenarios × 5 attributes
= 3125 data elements for analysis. Our methods will ad-
just for dependency of responses within individuals
(autoregression) as they respond to different choice sets
and will be modeled after published DCEs according to
the following example equation:
Utility ¼ constantð Þ þ β1 e:g:; physician autonomyð Þ
þ β2 e:g:; clinical timeð Þ…
We will assess for model fit and need for random pa-
rameters among the attributes. Attribute levels will
range from − 1 for our reference level to + 1 for the al-
ternative to allow determination of relative importance.
Our outcomes will be based on the beta parameter
values (β1, β2, etc.) and standard errors that correspond
to each attribute where a negative value will indicate
preference for the reference group, statistical significance
will be set at 0.05. Once we have our leading barrier at-
tributes and corresponding TDF domains, we will select
the most relevant candidate evidence-based behavior
change technique components based on prior work by
Michie et al. [49, 73] to guide tailoring of pilot
de-implementation interventions. We also plan to adjust
our models for facility-level ADT rates, and perform a
subgroup analysis for facilities with high primary ADT
rates to better understand barriers to tailor toward
(Table 1).
Broad intervention strategies require tailored design:
formulary restriction and decision-making
There are several potential implementation strategies to
de-implement low value castration within the broad cat-
egories we identified for this proposal. We focus on for-
mulary restriction and informed decision-making
because of their difference in key attributes, including
level (organizational vs. individual), likelihood of quick
success vs. long-term sustainment, and effort required
by clinicians. We describe some possible strategy design
features briefly for each type in Table 2. While several
options exist, there is no existing evidence to inform the
best approach from the provider perspective. Aims 1
and 2 will inform which of these strategies is likely to be
most acceptable to clinicians, and provide data needed
to tailor them. For example, we do not know how a
blunt formulary restriction intervention would be re-
ceived by providers considering primary ADT treatment.
While formulary restriction of ADT for localized pros-
tate cancer seems warranted, we may find that it is
widely considered unacceptable to providers and pa-
tients. Nor do we know how shared or informed
decision-making can be efficiently operationalized in a
clinical setting for patients considering castration for lo-
calized disease. By tailoring each strategy using behavior
change techniques and barrier solutions derived from
Aims 1 and 2, we believe we can design implementation
interventions that will be accepted by providers, but still
allow us to test differences in the widely varying mecha-
nisms of action. We will refine these approaches through
robust efforts and finding from Aims 1 and 2 (Table 1)
and the expertise of our trans-disciplinary investigative
team.
Aim 3 methods
Based on findings from Aims 1 and 2, Aim 3 pilot work
plays a critical role to help us understand the acceptabil-
ity, feasibility, and scalability of these complex
Table 1 Data sources and variables
Information Source Variables
Aim 1
Barriers and facilitators to stopping low
value chemical castration
12–16 urologists, selected patients from high and a
few low ADT facilities
Semi-structured interview data coded into themes
and TDF domains for use in Aim 2
Aim 2
Themes, barriers, attributes for discrete
choice scenarios
TDF domains and themes related to treating localized
prostate cancer with ADT from Aim 1
4–6 attributes with varying levels (e.g., physician
autonomy, clinical time)
Discrete choice experiment (DCE) Mixed multinomial logit analysis of DCE survey results
among national sample of urologists
Choice sets, attributes, model outcomes (barrier
attribute weights)
Behavior change techniques for most
relevant attributes for Aim 3
Michie et al. The Behavior Change Wheel: A Guide to
Designing Interventions [72]
Relevant TDF domains from the DCE model
output for use in tailoring strategies
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interventions in preparation for a full-scale randomized
de-implementation evaluation trial. In fact, the UK Medical
Research Council guidance indicates piloting is essential to
complex intervention development and testing prior to
large-scale evaluation [47]. The main goal of both pilots will
be to decrease castration rates for patients with localized
prostate cancer, in a way that is acceptable to patients and
to the clinicians who treat these patients. We are purposely
choosing intervention strategies from opposite ends of
the behavior change continuum because of their
evidence-based potential to change provider behavior. Spe-
cifically, we are selecting one approach (formulary restric-
tion policy) that operates at the organizational level and is
widely perceived as a forcing function, giving providers little
leeway to exercise judgment. The other, physician/patient
shared or informed decision-making, operates at an individ-
ual and dyadic level, and is perceived as maximizing the op-
portunity for discussions between patients and providers.
The first approach requires little to no learning on the part
of providers, while the second requires considerable up-
front learning (“cost” to the provider and possibly also to
the patient). This approach sets up a testable hypothesis for
our subsequent comparative effectiveness trial, that a blunt
de-implementation policy may be effective in the short
term but that it will lose its effects as providers learn
work-arounds. Conversely, a shared or informed
decision-making approach to de-implementation might
take longer to observe measurable decreases in castration
rates, but its effects will create sustainable change as pro-
viders internalize and routinize this clinical practice.
Methodological issues to be addressed in de-
implementation pilots
A well-designed pilot study has many purposes, includ-
ing testing methods of recruitment, selecting the most
appropriate primary outcome, testing acceptability of the
intervention by stakeholders, ironing out feasibility and
fidelity issues, developing the full study protocol, and es-
timating sample size for a full trial [70]. As highlighted
in implementation literature, preparation and planning
are central to successful pilot development and imple-
mentation [47, 58, 80]. The need for clear outcomes
(e.g., inappropriate castration rate), systematic,
theory-based interventions to change provider behavior
(i.e., TDF-driven), and a timetable are necessary to suc-
cessfully set up our full-scale evaluation trial. Although
it is likely that chemical castration rates among prostate
cancer patients will be our primary outcome for the full
evaluation trial (# of primary ADT patients with local-
ized prostate cancer/total incident prostate cancer pa-
tients), we will also need to consider implementation
outcomes (e.g., feasibility) and hybrid study designs. Fur-
ther refinement in the pilot studies will allow us to ex-
plore other outcomes including the total number of
ADT injections as we will also be working to stop treat-
ment among those with localized disease who have been
continued on ADT. As illustrated in Table 3, the piloting
of the intervention strategies will focus on four major
methodological issues. We will examine issues surround-
ing recruitment, acceptability, feasibility, scalability, and
data collection for the full-scale trial [66].
Discussion
Many men with prostate cancer are castrated with
long-acting injectable drugs. Although some patients
benefit, it is also used in patients who have little or noth-
ing to gain, such as men with localized prostate cancer.
The best ways to stop, or de-implement, low value cancer
care are unknown. A significant scientific and clinical
knowledge gap remains in prioritizing which barriers to
stopping castration in low value settings need to be tar-
geted for effective de-implementation. Using a mixed
methods approach, we will identify, refine, and pilot two
different approaches for reducing low value ADT use in
preparation for a randomized comparative effectiveness
trial. In doing so, this proposal will address important is-
sues surrounding provider behavior change and serve as a
model to decrease overtreatment more broadly. Through-
out this project, we will keep a broad focus so that our
work lays a foundation for transforming how and why cas-
tration is performed for prostate cancer treatment. This
work will advance de-implementation science for low
value care and foster participation in our subsequent
de-implementation evaluation trial by addressing prefer-
ences and concerns through pilot tailoring.
Dissemination
While the next steps for this work will be a cluster ran-
domized comparative effectiveness trial, setting up this
Table 2 Examples of potential pilot de-implementation
interventions
Formulary restriction
Prior authorization
- Oncology consultation
- Pharmacy review
Used in infectious disease
Criteria for use
- EMR order template
- Selected prescribers
Currently used for restricted drugs
Medication safety (VAMedSAFE) Evaluate, educate, and prevent
adverse events
Decision-making
Decision aid using a brief in-office
pro/con (e.g., Option Grid™)
Commercialized shared decision-
making for prostate cancer
Provider training in communication
and values elicitation
Evidence-based practice though
difficult to implement/sustain
Informed consent for ADT VA iMed consent
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complex trial will create opportunities for dissemination.
We will publish at least one manuscript per research
aim in peer-reviewed journals, as well as submit at least
one abstract to clinical, quality improvement, and/or im-
plementation research meetings. We will convene a
Steering Committee and update this group through
quarterly phone calls as we progress through the re-
search plan. In addition, we will present our findings to
the American Society of Clinical Oncology, Society of
Urologic Oncology, and the Association of VA
Hematology/Oncology as an opportunity to include a
de-implementation of low value cancer care theme in
their annual meeting agendas. We will brief relevant op-
erational partners annually including the VA National
Program Director for Oncology and the VA National Ur-
ology Surgery Advisory Board. We will also share our
findings and recruit for our cluster RCT at the Annual
AUA Meeting.
Trial status
Provider recruitment for Aim 1 started in August 2018.
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